INmune Bio/$INMB
1D1W1MYTD1Y5YMAX
About INmune Bio
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
- Ticker
- $INMB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 21
- Headquarters
- Boca Raton, United States
- Website
- www.inmunebio.com
INmune Bio Metrics
BasicAdvanced
$67M
-
-$0.69
0.90
-
Price and volume
Market cap
$67M
Beta
0.9
52-week high
$2.48
52-week low
$1.09
Average daily volume
397K
Financial strength
Current ratio
4.041
Quick ratio
3.935
Long term debt to equity
2.912
Total debt to equity
6.9
Profitability
Management effectiveness
Return on assets (TTM)
-39.12%
Return on equity (TTM)
-74.82%
Valuation
Price to book
3.3
Price to tangible book (TTM)
3.3
Price to free cash flow (TTM)
-4.115
Free cash flow yield (TTM)
-24.30%
Free cash flow per share (TTM)
-0.59
Growth
Revenue change (TTM)
-100.00%
Earnings per share change (TTM)
-72.52%
3-year earnings per share growth (CAGR)
-22.44%
What the Analysts think about INmune Bio
Analyst ratings (Buy, Hold, Sell) for INmune Bio stock.
INmune Bio Financial Performance
Revenues and expenses
INmune Bio Earnings Performance
Company profitability
INmune Bio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.